Aquestive Therapeutics CEO sells $105,600 in shares
Reported by Investing.com · investing.com ·
Story context
What to watch: This report cites a concrete figure ($105,600) — compare it against the trailing trend before treating one data point as a turning point.
Latest session change: $AQST -6.16%
How this was labelled
Investing.com published this one, and Wook filed it under Healthcare & Pharma. The automated reading is neutral, at low severity. It was matched to $AQST. The headline or preview carried 1 figure — $105,600 — shown above exactly as published. Nothing was recalculated. The publisher gave no preview text for this story, so only the headline appears above. Nothing has been written in to fill the gap.
When it landed
This one landed while New York was open, so the move shown beside it is a move the market could have been making as the story went round.
Where the price is
$AQST last traded at $3.81, -6.16% on the session. That is in the lower part of its 52-week range; the year runs $2.93 to $7.55. These are latest-session quotes, not live prices.
How much is being written
Wook has stored 2 stories about these names in the last 30 days, 2 of them this week. Most of that arrived in the last week, so the coverage is concentrated rather than steady. Across the whole run the wording has leaned bullish: 50% bullish, 50% neutral, 0% bearish. Only this one came from Investing.com, so the run is spread across outlets rather than driven by a single desk. 12 are listed beside this one if you want to follow the trail yourself.
What is already on the calendar
$AQST earnings in 19 days. These are dates Wook already holds for the companies in this story. They are here because they are scheduled, not because this story has anything to do with them.
What this page is not saying
The tone and severity labels come from matching the headline and preview against a fixed word list — no editor and no AI — so they describe how a story is worded, not what it will do, and the tone percentages above count wording rather than anyone's view. They are not a forecast, not a member vote, and not a recommendation. Any figures are copied from the headline or preview rather than worked out here, and a price move on the same day does not mean this story caused it. None of this is investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.